Year All20242023 Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates November 14, 2024 PDF Version Read More Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer October 24, 2024 PDF Version Read More Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates September 30, 2024 PDF Version Read More Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors September 10, 2024 PDF Version Read More FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed August 5, 2024 PDF Version Read More Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X July 30, 2024 PDF Version Read More Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea May 30, 2024 PDF Version Read More Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder May 7, 2024 PDF Version Read More Incannex Healthcare Inc. Quarterly Update, Q1 2024 April 16, 2024 PDF Version Read More Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder February 28, 2024 PDF Version Read More ASX Announcements
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates November 14, 2024 PDF Version Read More
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer October 24, 2024 PDF Version Read More
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates September 30, 2024 PDF Version Read More
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors September 10, 2024 PDF Version Read More
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed August 5, 2024 PDF Version Read More
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X July 30, 2024 PDF Version Read More
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea May 30, 2024 PDF Version Read More
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder May 7, 2024 PDF Version Read More
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder February 28, 2024 PDF Version Read More
